XML 67 R54.htm IDEA: XBRL DOCUMENT v3.25.1
Note 11 - Related-party Transactions (Details Textual) - USD ($)
$ in Thousands
1 Months Ended 9 Months Ended 12 Months Ended
Aug. 31, 2024
Aug. 30, 2024
Jun. 15, 2021
Feb. 18, 2019
Aug. 11, 2017
Aug. 31, 2024
Oct. 31, 2023
Sep. 30, 2023
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Oct. 31, 2024
Mar. 14, 2023
Research and Development Expense, Total                 $ 3,255 $ 3,322 $ 3,996    
Messa Holdings LLC [Member]                          
Equity Method Investment, Ownership Percentage                 50.00%        
FDA-Approved ANDA For Nitisinone [Member]                          
Payments to Acquire Marketing Rights             $ 150            
Commitment, Allocation of Profits, Percentage             80.00%            
Obligation Based on Acceptance of FDA of NDA for product [Member] | FDA-Approved ANDA For Nitisinone [Member]                          
Payments to Acquire Marketing Rights             $ 500            
Tulex Pharmaceuticals, Inc. (“Tulex”) [Member] | Obligation Based on First Commercial Sale of Product [Member]                          
Other Commitment                         $ 250
Tulex Pharmaceuticals, Inc. (“Tulex”) [Member] | Obligation Based on Acceptance of FDA of NDA for product [Member]                          
Other Commitment                         $ 200
Selenix [Member] | DS-200 [Member]                          
Commitment, Allocation of Profits, Percentage 45.00% 50.00%       45.00%              
U.S. and Canadian rights to Crossject S.A.’s [Member] | Crossject [Member]                          
Research and Development Expense, Total     $ 500                    
Royalty on Net Sales of Products, Percent     10.00%                    
Related Party, Eyemax LLC [Member] | The Eyemax Agreement [Member]                          
Related Party Transaction, Terms (Year)         10 years                
Related Party Transaction, Terms, Renewal (Year)         2 years                
Related Party, Eyemax LLC [Member] | The Eyemax Agreement [Member] | Research and Development Expense [Member]                          
Related Party Transaction, Amounts of Transaction         $ 250                
Related Party, Eyemax LLC [Member] | The Amended Agreement [Member]                          
Related Party Transaction, Amounts of Transaction                 $ 0 $ 0      
Revenues               $ 1,840          
Related Party, Bausch Health [Member] | Royalty [Member]                          
Related Party Transaction, Rate       12.00%                  
Chief Executive Officer [Member] | Sean E. Brynjelsen [Member]                          
Subsidiary, Ownership Percentage, Parent                 100.00%        
Related Party [Member]                          
Other Liabilities, Current                       $ 220